{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:20:35Z","timestamp":1771885235208,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR056246"],"award-info":[{"award-number":["AR056246"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR068353"],"award-info":[{"award-number":["AR068353"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA203011"],"award-info":[{"award-number":["CA203011"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disruption of bone homeostasis caused by metastatic osteolytic breast cancer cells increases inflammatory osteolysis and decreases bone formation, thereby predisposing patients to pathological fracture and cancer growth. Alteration of osteoblast function induces skeletal diseases due to the disruption of bone homeostasis. We observed increased activation of pERK1\/2 in osteolytic breast cancer cells and osteoblasts in human pathological specimens with aggressive osteolytic breast cancer metastases. We confirmed that osteolytic breast cancers with high expression of pERK1\/2 disrupt bone homeostasis via osteoblastic ERK1\/2 activation at the bone-breast cancer interface. The process of inflammatory osteolysis modulates ERK1\/2 activation in osteoblasts and breast cancer cells through dominant-negative MEK1 expression and constitutively active MEK1 expression to promote cancer growth within bone. Trametinib, an FDA-approved MEK inhibitor, not only reduced breast cancer-induced bone destruction but also dramatically reduced cancer growth in bone by inhibiting the inflammatory skeletal microenvironment. Taken together, these findings suggest that ERK1\/2 activation in both breast cancer cells and osteoblasts is required for osteolytic breast cancer-induced inflammatory osteolysis and that ERK1\/2 pathway inhibitors may represent a promising adjuvant therapy for patients with aggressive osteolytic breast cancers by altering the shared cancer and bone microenvironment.<\/jats:p>","DOI":"10.1038\/s41413-021-00158-w","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T11:09:58Z","timestamp":1632913798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1\/2 aggravates cancer-induced bone destruction"],"prefix":"10.1038","volume":"9","author":[{"given":"Jungho","family":"Back","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh Nam","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saelim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fancheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Gillinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Ho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-4188","authenticated-orcid":false,"given":"Kareme D.","family":"Alder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-4061","authenticated-orcid":false,"given":"Hyuk-Kwon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-5200","authenticated-orcid":false,"given":"Kristin E.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Dussik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuchukwu K.","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana M.","family":"Munger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Wook","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"158_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"158_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2009.0080","volume":"7","author":"A Lipton","year":"2009","unstructured":"Lipton, A. et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl Compr. Canc Netw. 7, S1\u2013S30 (2009).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"158_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5301\/HIP.2011.8654","volume":"21","author":"MJ Parker","year":"2011","unstructured":"Parker, M. J., Khan, A. Z. & Rowlands, T. K. Survival after pathological fractures of the proximal femur. Hip. Int. 21, 526\u2013530 (2011).","journal-title":"Hip. Int."},{"key":"158_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong, M. et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res. Treat. 129, 495\u2013503 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"158_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3111\/13696998.2014.890937","volume":"17","author":"M Hagiwara","year":"2014","unstructured":"Hagiwara, M., Delea, T. E. & Chung, K. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. J. Med. Econ. 17, 223\u2013230 (2014).","journal-title":"J. Med. Econ."},{"key":"158_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/ecp.12.21","volume":"5","author":"JA Ford","year":"2012","unstructured":"Ford, J. A., Mowatt, G. & Jones, R. Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Rev. Clin. Pharm. 5, 271\u2013279 (2012).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"158_CR7","first-page":"276","volume":"5","author":"J Dutka","year":"2003","unstructured":"Dutka, J. & Sosin, P. Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortop. Traumatol. Rehabil. 5, 276\u2013283 (2003).","journal-title":"Ortop. Traumatol. Rehabil."},{"key":"158_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2013.36","volume":"9","author":"RE Coleman","year":"2013","unstructured":"Coleman, R. E., Rathbone, E. & Brown, J. E. Management of cancer treatment-induced bone loss. Nat. Rev. Rheumatol. 9, 365\u2013374 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"158_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u2013425 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"158_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1359\/jbmr.2003.18.4.599","volume":"18","author":"M Zaidi","year":"2003","unstructured":"Zaidi, M., Blair, H. C., Moonga, B. S., Abe, E. & Huang, C. L. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J. Bone Min. Res. 18, 599\u2013609 (2003).","journal-title":"J. Bone Min. Res."},{"key":"158_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin, J. J. et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig. 103, 197\u2013206 (1999).","journal-title":"J. Clin. Investig."},{"key":"158_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","volume":"19","author":"N Sethi","year":"2011","unstructured":"Sethi, N., Dai, X., Winter, C. G. & Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192\u2013205 (2011).","journal-title":"Cancer Cell"},{"key":"158_CR13","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1158\/0008-5472.CAN-06-2355","volume":"67","author":"T Hiraga","year":"2007","unstructured":"Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M. & Yoneda, T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67, 4157\u20134163 (2007).","journal-title":"Cancer Res."},{"key":"158_CR14","doi-asserted-by":"publisher","first-page":"404810","DOI":"10.1155\/2012\/404810","volume":"2012","author":"C Chandhanayingyong","year":"2012","unstructured":"Chandhanayingyong, C., Kim, Y., Staples, J. R., Hahn, C. & Lee, F. Y. MAPK\/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: therapeutic Implications and Future Directions. Sarcoma 2012, 404810 (2012).","journal-title":"Sarcoma"},{"key":"158_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.bone.2009.10.032","volume":"46","author":"SW Seo","year":"2010","unstructured":"Seo, S. W. et al. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone 46, 695\u2013702 (2010).","journal-title":"Bone"},{"key":"158_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577\u2013592 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"158_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","volume":"1754","author":"B Kaminska","year":"2005","unstructured":"Kaminska, B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy\u2212from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754, 253\u2013262 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"158_CR18","first-page":"125705","volume":"2013","author":"MN Weitzmann","year":"2013","unstructured":"Weitzmann, M. N. The Role of Inflammatory Cytokines, the RANKL\/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Sci. (Cairo) 2013, 125705 (2013).","journal-title":"Sci. (Cairo)"},{"key":"158_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1359\/jbmr.2003.18.5.827","volume":"18","author":"K Nakayama","year":"2003","unstructured":"Nakayama, K. et al. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J. Bone Min. Res. 18, 827\u2013835 (2003).","journal-title":"J. Bone Min. Res."},{"key":"158_CR20","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/jbmr.2002.17.10.1785","volume":"17","author":"C Higuchi","year":"2002","unstructured":"Higuchi, C. et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J. Bone Min. Res. 17, 1785\u20131794 (2002).","journal-title":"J. Bone Min. Res."},{"key":"158_CR21","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1128\/MCB.01549-08","volume":"29","author":"T Matsushita","year":"2009","unstructured":"Matsushita, T. et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell Biol. 29, 5843\u20135857 (2009).","journal-title":"Mol. Cell Biol."},{"key":"158_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6694","volume":"5","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).","journal-title":"Nat. Commun."},{"key":"158_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000488087","volume":"41","author":"K Zirlik","year":"2018","unstructured":"Zirlik, K. & Duyster, J. Anti-Angiogenics: current situation and future perspectives. Oncol. Res. Treat. 41, 166\u2013171 (2018).","journal-title":"Oncol. Res. Treat."},{"key":"158_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","volume":"76","author":"R von Moos","year":"2019","unstructured":"von Moos, R. et al. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat. Rev. 76, 57\u201367 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"158_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/intimm\/dxq431","volume":"22","author":"YM Lee","year":"2010","unstructured":"Lee, Y. M., Fujikado, N., Manaka, H., Yasuda, H. & Iwakura, Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int. Immunol. 22, 805\u2013816 (2010).","journal-title":"Int. Immunol."},{"key":"158_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721\u2013729 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"158_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S8756-3282(03)00086-3","volume":"33","author":"MS Bendre","year":"2003","unstructured":"Bendre, M. S. et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33, 28\u201337 (2003).","journal-title":"Bone"},{"key":"158_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-13-2645","volume":"74","author":"SW Olechnowicz","year":"2014","unstructured":"Olechnowicz, S. W. & Edwards, C. M. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res. 74, 1625\u20131631 (2014).","journal-title":"Cancer Res."},{"key":"158_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/107327481201900203","volume":"19","author":"RL Theriault","year":"2012","unstructured":"Theriault, R. L. & Theriault, R. L. Biology of bone metastases. Cancer Control 19, 92\u2013101 (2012).","journal-title":"Cancer Control"},{"key":"158_CR30","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"JC Chambard","year":"2007","unstructured":"Chambard, J. C., Lefloch, R., Pouyssegur, J. & Lenormand, P. ERK implication in cell cycle regulation. Biochim. Biophys. Acta 1773, 1299\u20131310 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"158_CR31","doi-asserted-by":"publisher","first-page":"47366","DOI":"10.1074\/jbc.M208284200","volume":"277","author":"H Hotokezaka","year":"2002","unstructured":"Hotokezaka, H. et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem. 277, 47366\u201347372 (2002).","journal-title":"J. Biol. Chem."},{"key":"158_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1373\/clinchem.2012.185363","volume":"59","author":"NE Sounni","year":"2013","unstructured":"Sounni, N. E. & Noel, A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 59, 85\u201393 (2013).","journal-title":"Clin. Chem."},{"key":"158_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"CJ Logothetis","year":"2005","unstructured":"Logothetis, C. J. & Lin, S. H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5, 21\u201328 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"158_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ijc.28965","volume":"137","author":"A Mathew","year":"2015","unstructured":"Mathew, A. & Brufsky, A. Bisphosphonates in breast cancer. Int J. Cancer 137, 753\u2013764 (2015).","journal-title":"Int J. Cancer"},{"key":"158_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000338650","volume":"7","author":"M Gnant","year":"2012","unstructured":"Gnant, M. et al. Treatment of Bone Metastases in Patients with Advanced Breast Cancer. Breast Care (Basel) 7, 92\u201398 (2012).","journal-title":"Breast Care (Basel)"},{"key":"158_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron, R., Ferrari, S. & Russell, R. G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48, 677\u2013692 (2011).","journal-title":"Bone"},{"key":"158_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2042098611411012","volume":"2","author":"C McGreevy","year":"2011","unstructured":"McGreevy, C. & Williams, D. Safety of drugs used in the treatment of osteoporosis. Ther. Adv. Drug Saf. 2, 159\u2013172 (2011).","journal-title":"Ther. Adv. Drug Saf."},{"key":"158_CR38","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina, C. V. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294\u20131301 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"158_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jama.2011.190","volume":"305","author":"LY Park-Wyllie","year":"2011","unstructured":"Park-Wyllie, L. Y. et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305, 783\u2013789 (2011).","journal-title":"JAMA"},{"key":"158_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar, K. S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 17, 48 (2018).","journal-title":"Mol. Cancer"},{"key":"158_CR41","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/JCI76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross, S., Rahal, R., Stransky, N., Lengauer, C. & Hoeflich, K. P. Targeting cancer with kinase inhibitors. J. Clin. Investig. 125, 1780\u20131789 (2015).","journal-title":"J. Clin. Investig."},{"key":"158_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1947601911407328","volume":"2","author":"I Wortzel","year":"2011","unstructured":"Wortzel, I. & Seger, R. The ERK Cascade: distinct Functions within Various Subcellular Organelles. Genes Cancer 2, 195\u2013209 (2011).","journal-title":"Genes Cancer"},{"key":"158_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu, F., Yang, X., Geng, M. & Huang, M. Targeting ERK, an Achilles\u2019 Heel of the MAPK pathway, in cancer therapy. Acta Pharm. Sin. B 8, 552\u2013562 (2018).","journal-title":"Acta Pharm. Sin. B"},{"key":"158_CR44","doi-asserted-by":"publisher","first-page":"9197","DOI":"10.1016\/j.biomaterials.2011.08.059","volume":"32","author":"HG Lee","year":"2011","unstructured":"Lee, H. G. et al. Actin and ERK1\/2-CEBPbeta signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials 32, 9197\u20139206 (2011).","journal-title":"Biomaterials"},{"key":"158_CR45","first-page":"6605","volume":"17","author":"G Luo","year":"2018","unstructured":"Luo, G., Li, F., Li, X., Wang, Z. G. & Zhang, B. TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway. Mol. Med. Rep. 17, 6605\u20136611 (2018).","journal-title":"Mol. Med. Rep."},{"key":"158_CR46","first-page":"3955","volume":"63","author":"A Gorden","year":"2003","unstructured":"Gorden, A. et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63, 3955\u20133957 (2003).","journal-title":"Cancer Res."},{"key":"158_CR47","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","volume":"18","author":"S Dogan","year":"2012","unstructured":"Dogan, S. et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res. 18, 6169\u20136177 (2012).","journal-title":"Clin. Cancer Res."},{"key":"158_CR48","first-page":"275","volume":"17","author":"JM Giltnane","year":"2014","unstructured":"Giltnane, J. M. & Balko, J. M. Rationale for targeting the Ras\/MAPK pathway in triple-negative breast cancer. Disco. Med. 17, 275\u2013283 (2014).","journal-title":"Disco. Med."},{"key":"158_CR49","first-page":"153","volume":"22","author":"G Pearson","year":"2001","unstructured":"Pearson, G. et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153\u2013183 (2001).","journal-title":"Endocr. Rev."},{"key":"158_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107\u2013114 (2012).","journal-title":"N. Engl. J. Med."},{"key":"158_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11914-015-0266-z","volume":"13","author":"MD Wissing","year":"2015","unstructured":"Wissing, M. D. Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Curr. Osteoporos. Rep. 13, 140\u2013145 (2015).","journal-title":"Curr. Osteoporos. Rep."},{"key":"158_CR52","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/jcp.23034","volume":"227","author":"T Shandala","year":"2012","unstructured":"Shandala, T. et al. The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J. Cell Physiol. 227, 2889\u20132897 (2012).","journal-title":"J. Cell Physiol."},{"key":"158_CR53","doi-asserted-by":"publisher","first-page":"e36739","DOI":"10.1371\/journal.pone.0036739","volume":"7","author":"Z Deng","year":"2012","unstructured":"Deng, Z., Sui, G., Rosa, P. M. & Zhao, W. Radiation-induced c-Jun activation depends on MEK1-ERK1\/2 signaling pathway in microglial cells. PLoS One 7, e36739 (2012).","journal-title":"PLoS One"},{"key":"158_CR54","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","volume":"18","author":"JS Khalili","year":"2012","unstructured":"Khalili, J. S. et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18, 5329\u20135340 (2012).","journal-title":"Clin. Cancer Res."},{"key":"158_CR55","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929\u2013935 (2019).","journal-title":"Nat. Med"},{"key":"158_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"158_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/vaccines4030022","volume":"4","author":"JM David","year":"2016","unstructured":"David, J. M., Dominguez, C., Hamilton, D. H. & Palena, C. The IL-8\/IL-8R Axis: a Double Agent in Tumor Immune Resistance. Vaccines (Basel) 4, 22 (2016).","journal-title":"Vaccines (Basel)"},{"key":"158_CR58","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Min. Res. 25, 1468\u20131486 (2010).","journal-title":"J. Bone Min. Res"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00158-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00158-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:37:29Z","timestamp":1706186249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00158-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1038\/s41413-021-00158-w","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}